|Bid||100.00 x 800|
|Ask||147.00 x 1000|
|Day's Range||130.00 - 135.11|
|52 Week Range||96.42 - 164.76|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
-Epidiolex ® oral solution approved by FDA and on track to be launched in Fall-- Conference call today at 4:30 p.m. ET-. LONDON and CARLSBAD, Calif., Aug. 07, 2018-- GW Pharmaceuticals plc, the world leader ...
HENDERSON, NV / ACCESSWIRE / August 3, 2018 / On June 25, the FDA approved London-based GW Pharma's Epidiolex, a drug containing CBD as its active ingredient, to treat two rare and severe forms of epilepsy, ...
CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, today announced publication of an article covering how cannabinoids are currently being used by physicians and how companies, such as Pascal Biosciences Inc. (PAS.V), are exploring new treatment options and combination therapies. The liberalization of cannabis laws around the world has opened the door for researchers to explore the therapeutic benefits of cannabinoids. Cannabinoids have been primarily used by physicians to treat the side-effects of cancer.
GW Pharmaceuticals plc (GWPH) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 7 August, 2018 its third quarter financial results for the period ending 30 June, 2018. GW will also host a conference call the same day at 4:30 p.m. EDT. A replay of the call will also be available through the Company's website (www.gwpharm.com) shortly after the call.
Microcapspeculators.com is an informational website that is highly interested in exploring development stage companies, enroute to finding companies with the best potential HENDERSON, NV / ACCESSWIRE / ...
NEW YORK, NY / ACCESSWIRE / July 10, 2018 / U.S. equities continued to push higher on Monday, as strong economic data counters worries on rising trade tensions. The Dow Jones Industrial Average advanced ...
NEW YORK, NY / ACCESSWIRE / June 29, 2018 / U.S. markets rebounded Thursday on the strength of the financial and technology sectors. The Dow Jones Industrial Average jumped 0.41 percent to close at 24,216.05, ...
VANCOUVER, British Columbia, June 27, 2018-- Isodiol International Inc., a global CBD innovator specializing in hemp-based health and wellness products, the development of pharmaceutical CBD delivery methods ...
NEW YORK, NY / ACESSWIRE / June 26, 2018 / It was a bad day for PolarityTE shares on Monday after short seller Citron Research asked upon the SEC to "halt this stock immediately" on claims that the company is a "fraud." Shares of GW Pharmaceuticals may have closed in the red yesterday but the company made history as its Epidiolex drug was the first marijuana-based drug to be approved by the FDA in the nation. GW Pharmaceuticals plc shares closed down 4.29% on almost 1.2 million shares traded on Monday.
GW Pharmaceuticals plc (GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced today that the U.S. Food and Drug Administration (FDA) has approved EPIDIOLEX® (cannabidiol) oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two years of age or older. EPIDIOLEX is the first prescription pharmaceutical formulation of highly-purified, plant-derived cannabidiol (CBD), a cannabinoid lacking the high associated with marijuana, and the first in a new category of anti-epileptic drugs (AEDs).
VANCOUVER , June 25, 2018 /CNW/ - Harvest One Cannabis Inc. (TSXV: HVT) ("Harvest One" or the "Company") has signed a binding Share Sale Agreement ("SSA") with Australian-based MMJ PhytoTech Limited ("MMJ") for the purchase of 100% of Israeli-based PhytoTech Therapeutics Ltd ("PhytoTech" or "PTL"). The transaction will be a combination of cash and shares. Upon completion, $1 million in cash and $7 million in Harvest One common shares issued at the then 10-day volume weighted average closing price, will be paid to MMJ.
NEW YORK, NY / ACCESSWIRE / June 20, 2018 / As Canada officially legalized recreational marijuana this week, shares of Canopy Growth skyrocketed after announcing a multi-year agreement with Neptune Technologies & Bioressources Inc. Shares of GW Pharmaceuticals were modestly in the red despite any news. Canopy Growth Corporation shares closed up almost 4% on Tuesday with nearly 4.5 million shares traded. The stock hit a brand new high of $32.88 yesterday after it was revealed that Neptune Technologies & Bioressources Inc. has entered into a multi-year agreement with Canopy Growth to supplement Canopy Growth's extraction, refinement, and extract product formulation capacity.
GW Pharmaceuticals plc (GWPH) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that GW management will present at the Goldman Sachs 39th Annual Global Healthcare Conference on Wednesday, June 13, 2018 at 10:00 a.m. PT at the Terranea Resort, in Rancho Palos Verde, CA. Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas.
NEW YORK, June 06, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Clementia ...
NEW YORK, NY / ACCESSWIRE / May 24, 2018 / U.S. markets rebounded modestly on Wednesday, following the release of Fed's minutes of the meeting, which suggest that the central bank will be slightly dovish ...
Major equities: AbbVie Inc. (NYSE: ABBV), Bristol-Myers Squibb Co. (NYSE: BMY), Eli Lilly and Co. (NYSE: LLY), and GW Pharmaceuticals PLC (NASDAQ: GWPH). All you have to do is sign up today for this free limited time offer by clicking the link below.
GW Pharmaceuticals plc (GWPH) ("GW," "the Company" or "the Group"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced today that The New England Journal of Medicine has published results from a Phase 3 study of cannabidiol oral solution in patients with Lennox-Gastaut syndrome (LGS), a rare, severe and difficult to treat form of childhood-onset epilepsy.1 Cannabidiol oral solution (CBD, Epidiolex®), is a pharmaceutical formulation of highly purified cannabidiol a cannabinoid lacking the high associated with cannabis. In this study, both evaluated doses of cannabidiol oral solution significantly reduced the monthly frequency of drop seizures compared to placebo in highly treatment-resistant patients when added to existing treatment.
NEW YORK, NY / ACCESSWIRE / April 18, 2018 / Markets continued to rise on Tuesday as investor focus continues to shift from geopolitical concerns to strong corporate earnings from major U.S. companies. ...